Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
brentuximab vedotin + pembrolizumab
- Development stage
- Phase 3
- Lead developer
- Pfizer
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Brentuximab vedotin + pembrolizumab is a combination therapy consisting of an antibody-drug conjugate (brentuximab vedotin) and an immune checkpoint inhibitor (pembrolizumab). Brentuximab vedotin targets CD30-expressing cells, delivering the cytotoxic agent monomethyl auristatin E (MMAE) which disrupts the microtubule network, inducing cell cycle arrest and apoptosis. Pembrolizumab is a PD-1 inhibitor that enhances T-cell immune responses against tumor cells. This combination is being investigated for its potential synergistic effects in treating various cancers, particularly in patients with relapsed/refractory disease.
- Other names
- KEYTRUDA + ADCETRIS
02
Targets
CD30 (CD30 antigen)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on brentuximab vedotin + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on brentuximab vedotin + pembrolizumab.